ðçãã€ãã«ã¡ã¯ãã³ããã§ã³ãã³ããŸãŒã«ãã¡ã³ãã³ããŸãŒã«ãããããã·ã¯ãããã³
ããããã·ã¯ãããã³ãšã€ãã«ã¡ã¯ãã³
ããæ²»çè¬ã®åå©çš
ãã§ã³ãã³ãã¹ããŒãž4ã®ç
2025/11/04 ãžã§ã³ã¯ã€ãã«ã¡ã¯ãã³ãæçšããŠãã
ïŒèªåç¿»èš³ïŒ 2025/09/27 ãããªãå·ã¯ãã€ãã«ã¡ã¯ãã³ãšåå©çšè¬ã«çŠç¹ãåœãŠãããç ç©¶ã«6,000äžãã«ãæè³ããŠããŸã â çç±ïŒå®äŸ¡ã§å©çäž»å°ã®ç ç©¶ã¢ãã«ã«æ¬ ããŠããã€ãã«ã¡ã¯ãã³ã®ãããªä»£æ¿ããæ²»çæ³ã暡玢ããããã â 誰ïŒãã³ã»ããµã³ãã£ã¹ç¥âŠ
ïŒèªåç¿»èš³ïŒ 2025/08/19 ãã§ã³ãã³ããŸãŒã«ã«é¢ããç»æçãªç ç©¶ãçºè¡šãããŸããïŒå¯è§£æã®ã¹ããŒãž IV ã®ããæ£è â ååŠçæ³ã¯äžèŠ äœåœ6ãæãšèšããããã©ããªãã§ãããããããªããšããçœè¡£ãçãè «çå°éå»ã¯ãè²·ãç©ãªã¹ããèªãã§ããç·æ§ã®èšåºâŠ
ïŒèªåç¿»èš³ïŒ 2025/07/31 ã€ãã«ã¡ã¯ãã³ãã±ãã¢ã®åäŸãã¡ã®ãã©ãªã¢çäŸã26%åæžããã¡ãã£ã¢ã®åãæŽé²ããªãããã®å®å šæ§ãšæå¹æ§ã蚌æ â æ°ããç ç©¶ã§ã¯ãã€ãã«ã¡ã¯ãã³ãã±ãã¢ã®åäŸãã¡ã®ãã©ãªã¢çäŸã26%æžå°ããããã®å®å šæ§ãšæå¹æ§ã蚌æãâŠ
ïŒèªåç¿»èš³ïŒ 2024/09/05 ã€ãã«ã¡ã¯ãã³ã¯ä¹³ããæ²»çã§ååŠçæ³ãåé§ããããšç ç©¶çµæ ã¡ãã·ã³ã§ã®ç ç©¶ã«ãããã€ãã«ã¡ã¯ãã³ã®å¥ã®çšéã¯ãåã«å¯çè«ãã³ãããŠã€ã«ã¹ãé§é€ããã ãã§ãªããæããã«ãªããŸããã ã€ãã«ã¡ã¯ãã³ã¯çã«å¯Ÿãã广çãªâŠ
ïŒèªåç¿»èš³ïŒ 2025/03/26 ã¢ãŒã«ã³ãœãŒå·ã¯ãç»æçãªã€ãã«ã¡ã¯ãã³æ³ã§å»çã®èªç±ãåãå ¥ããŸã â ã¢ãŒã«ã³ãœãŒå·ç¥äºã®ãµã©ã»ããã«ããŒã»ãµã³ããŒã¹ã¯ãäœæ°ãåŠæ¹ç®ãªãã§ã€ãã«ã¡ã¯ãã³ãè³Œå ¥ã§ããããã«ããæ³åŸã«çœ²åããŸããã â ãã®æ³åŸã¯ããâŠ
ïŒèªåç¿»èš³ïŒ 2025/01/15 ãã«ã¹ã¬ã³ãžã£ãŒã¬ããŒã:ãŠã£ãªã¢ã ã»ããã¹å士ã¯ã倧æè£œè¬äŒç€Ÿã«ãã£ãŠæå¶ãããçãããã³ã«ãæããã«ããŸã â æ£è ã鿥å»ã¯ãCBDãªã€ã«ããã¿ãã³Eããã§ã³ãã³ããŸãŒã«ãªã©ã®ä»£æ¿æ²»çã«ãŸããŸãç®ãåããŠãããäž»æµã®âŠ
ïŒèªåç¿»èš³ïŒ 2024/07/11 人ã ã¯ãå¯çè«ã殺ãäžè¬çãªç£å»åŠã§ãããã§ã³ãã³ããŸãŒã«ã§èµèçãæ²»ããŠãããšäž»åŒµããŠããŸã 2023幎8æã«ã¹ããŒãž4ã®èµèãããšèšºæããã人ã¯ããã§ã³ãã³ããŸãŒã«(Panacur C)ãšããŠç¥ãããäžè¬çãªç£å»åŠã䜿çšããŠç æ°âŠ
ïŒèªåç¿»èš³ïŒ 2024/12/15 ãã€ã¯ã»ã¢ãã ã¹ïŒæ¬¡ã®ãã³ãããã¯ã¯ãããªããéšãããã¹ãã§ã¯ãªãææã«åºã¥ãå¿çäœæŠã§ã â ãã«ã¹ã¬ã³ãžã£ãŒã®ãã€ã¯ã»ã¢ãã ã¹ã¯ã次ã®ãã³ãããã¯ã¯ãã°ããŒããªã¹ãã®ã¢ãžã§ã³ãã«åŸãããã«å€§è¡ãæäœããçæŽ»ãã³ã³ãâŠ
ïŒèªåç¿»èš³ïŒ 2024/09/06 ãµããŒãã»ãã¶ã³å士ãCOVIDã®ãã¯ã¯ãã³ãã«ãã£ãŠéèŠãªè žå 现èãæ¶æ» ããããšãæããã« æ¶ååšå ç§å»ã®ãµããŒãã»ãã¶ã³å士ã¯ãæŠæŒ¢ã³ãããŠã€ã«ã¹(COVID-19)ã®ãã¯ã¯ãã³æ¥çš®ããåããå»åž«ã®è žå 现èå¢ã詳ãã調ã¹ãåŸãâŠ
èªå翻蚳ïŒ2024/10/16ã€ãã«ã¡ã¯ãã³ãã¡ãã³ããŸãŒã«ããã§ã³ãã³ããŸãŒã«ã®æãã广ã«é¢ããäžçåã®æ»èªä»ãç ç©¶ãè©å€ã®è¯ããžã£ãŒãã«ã«æ²èŒãããŸãã 2024幎9æ19æ¥ãInternational Journal of Orthomolecular Medicineèªã«çºè¡šãããç ç©¶è«æãçºâŠ
ïŒèªåç¿»èš³ïŒ 2024/09/25 COVID VACCINEã®çã¿ã®èŠªã§ããç±³è»ã¯ã2016幎ãããã§ã«ãã€ãã«ã¡ã¯ãã³ããã³ãããã¯ã®éã«äœ¿çšããã®ã«æé©ãªè£œåã§ããããšãç¥ã£ãŠããŸãã ã«ããå šåã§ææ¥å»ããã³äžè¬ç é¢ã®å»åž«ã§ããã¯ãªã¹ããã¡ãŒã»ã·ã¥ãŒã¡ãŒã«ãŒåâŠ
ïŒèªåç¿»èš³ïŒ 2024/08/30 ããç ç©¶è :ã€ãã«ã¡ã¯ãã³ã¯mRNAã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ããããTURBO CANCERSã®ååŠçæ³èæ§ãå æããããšãã§ããŸã è «çåŠè ãããç ç©¶è ãèè ã¯æè¿ããã¡ã€ã¶ãŒç€Ÿãšã¢ãã«ãç€Ÿã®æŠæŒ¢ã³ãããŠã€ã«ã¹(COVID-19)mRNAã¯ã¯ãã³ã«âŠ
æ¥æ¬äººãè£ ãç¶ããä¿å®ãè£ ã£ãŠããè ãå€ãããŸãã çãããç¥ã£ãŠããããã¡ã§ãã圌ãã¯åã¹ãã€ã§ãã ãªãã£ãŒãã»ã³ã·ããºã¯ç¹ã«ã€ãã«ã¡ã¯ãã³ãæšå¥šããŠããŸãã èšäºãæåãããŠé ããŸãããããããšãããããŸãã ãã€ã¯ã»ã€ã§ãŒãã³å士ã€ãâŠ
ïŒèªåç¿»èš³ïŒ 2024/07/08 ã€ãã«ã¡ã¯ãã³ã¯ãããŒãã³ãœã³ç ããã€ç ãæ ¢æ§çŒçãªã©ã«å¹æãããããšãããã£ãŠããŸã ã€ãã«ã¡ã¯ãã³ãã§ããããšã¯ãæŠæŒ¢ã³ãããŠã€ã«ã¹(COVID-19)ã®äºé²ãšæ²»çã ãã§ã¯ãããŸãããå»åž«ãäœå®¶ã人暩æè·è ã§ãããžã£ã¹ãã¥âŠ
èšäºãæåãããŠé ããŸãããããããšãããããŸãã ãªãã£ãŒãã»ã³ã·ããºïŒèŠªäžæŽŸã®å·¥äœå¡ã éåïŒèŒ¿æ°Žæ£ æ¬åïŒæè© é²
ïŒèªåç¿»èš³ïŒ ã¡ã¢ãªãŒã»ã¿ãªãŒã»ããŠãã³å士ã¯ãã€ãã«ã¡ã¯ãã³ã¯æ£è ãCOVIDãžã£ãã«ãããã¡ãŒãžãå æããã®ã«åœ¹ç«ã£ãŠãããšè¿°ã¹ãŠããŸã 2020幎åŸåã®ã¯ãŒãã¹ããŒãäœæŠã®éå§ã¯ãæ·±å»ã§äžèŠäžå¯è§£ãªå ¬è¡è¡çäžã®å±æ©ã«ç¶ãæ°å¹Žéã«ããããããŸããâŠ
2022/01/02 ïŒèªåç¿»èš³ïŒ æ¥æ¬ã®è£œè¬äŒç€Ÿã¯ãã€ãã«ã¡ã¯ãã³ããªãã¯ãã³ãä»ã®COVIDå€ç°äœã«å¯ŸããŠãæãŠã€ã«ã¹å¹æããæããããšãçºèŠ èåæ°ã¯ããã®æåãªè¬ã¯SARS-CoV2ã®æ¢åã®ãã¹ãŠã®æ ªã«å¯ŸããŠæãŠã€ã«ã¹ç¹æ§ãæããã³ãããŠã€ã«ã¹æ²»çè¬ãšããŠåºâŠ
2022/06/15 ïŒèªå翻蚳ãã³ããïŒ ããããŠã€ã«ã¹åŠè ã¯ããä»åŸ2ã¶æãã«ã¯ã¯ãã³æ¥çš®ãåãã人ã®ããã®èŽåœçãªCOVIDå€ç°ãäºæž¬ããŸã Geert Vanedn Bosscheå士ã¯ãCOVIDã®éå£äºé²æ¥çš®ãã£ã³ããŒã³ã«ããããŠã€ã«ã¹ãã¯ããã«å±éºãªç åäœã«å€ç°ããç¹âŠ